Merck Invests US$74.9 million (€70 million) to Expand Manufacturing Capacity in Missouri, USA
Introduction:
Merck is investing $74.9 million (€70 million) to enhance its ADC manufacturing capabilities and capacity at its bioconjugation center of excellence in St. Louis, Missouri, USA.
Features:
This investment will triple the current capacity and enhance the contract development and manufacturing organisation (CDMO) offerings, underscoring its commitment to patients.
With increased capacity and by scaling utilities as well as improving process and analytical development (PAD) labs, the facility will provide industry-leading support for early-stage and commercial bioconjugates.
The ADC capacity expansion project will:
- Upgrade 3,200 m² to benefit the process and analytical development, quality control, research and development, manufacturing, and logistics departments.
- Add new laboratories, a dedicated buffer preparation facility for manufacturing, and a cold storage area alongside a GMP-controlled room temperature (CRT) warehouse, all located near the existing facility.
Alongside recent expansions in footprint and capacity, the organisation continues to innovate differentiated technologies and platforms that enhance the potential of this novel modality.
This expanded scope highlights the transformative role of bioconjugates in advancing personalised medicine across various therapeutic areas.
Specifications:
| Name: | Merck |
| Type: | New Construction |
| Budget: | US$74.9 million (€70 million) |
